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Determining a protocol for treatment: Rate versus Rhythm Control in Atrial
Fibrillation – a Quality of Life Study.
Abstract
In the United States alone, approximately 6 million people are estimated to have atrial
fibrillation (AF)1. Those with AF are at a dangerously high risk for the development of stroke
and/or death from emboli that form secondary to the deadly arrhythmia. Much controversy
exists in the medical field surrounding the best way to treat AF to reduce both the associated
morbidity and mortality. This study sought to bring clarity to the controversy by analyzing
clinical trials comparing rhythm control vs. rate control of atrial fibrillation. Three studies were
used to evaluate which method better increased quality of life for those with AF. In general,
there was no clinically statistical difference in the improvement of morbidity or mortality, and
thus quality of life, between medical rate and rhythm control; though there may be trend
towards rhythm control in certain instances. In conclusion, the ultimate choice of which
treatment method to use rests heavily on each individual presentation of atrial fibrillation and
what is best for the patient specifically.

Introduction
According to the Centers for Disease Control and Prevention, atrial fibrillation (AF) is the
most common arrhythmia encountered in clinical practice, accounting for about 15% of all
arrhythmias.1 Nation-wide, between 2.7 and 6.1 million people are estimated to have this
arrhythmia.1 Though atrial fibrillation may be asymptomatic, it is associated with significant
morbidity and mortality, as it increases the risk of death and stroke, 2-fold and 4-5-fold
respectively.2 The two major risk factors for developing AF are hypertensive heart disease and
atherosclerotic cardiovascular disease.3 Other causes include alcohol intake, surgery,
electrocution, myocarditis, pulmonary embolism, other pulmonary diseases, and
hyperthyroidism. Successful treatment of these underlying causes typically results in resolution
of the AF.
Atrial fibrillation is notorious for thrombus development due to the failure of the heart
to efficiently pump blood - resulting in blood stasis and clot formation. When emboli become
dislodged, typically from the left atrial appendage, they can occlude parts of the brain, gut or
other peripheral circulation, resulting in clinical consequences such as: stroke, mesenteric
ischemia, and other embolic phenomena respectively. AF can also cause (or worsen) heart
failure, often manifesting as decreased exercise tolerance, syncope, shortness of breath or
chest pain.3 In addition to these health related quality of life issues, AF can have socioeconomic consequences. Patients often have to be on anticoagulant therapy that requires
lifelong follow up and accompanying heavy financial burden. In the US, the average annual cost
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attributable to the management of chronic AF to the individual is estimated at $8700, and to
the nation, about $6 billion.1
AF is classified according to the time period of occurrence, as new–onset, paroxysmal
(beginning and ending abruptly, usually lasting hours to less than 7 days), persistent (lasting
longer than 7 days) or permanent (when a clinical decision is made to not pursue rhythm
change but to control the rate only)4. AF often presents with an abnormally fast heart rate,
even at rest. Such patients are usually symptomatic and the heart rate must be controlled. A
typical heart rate goal is below 100 beats per minute, but the optimal heart rate depends on
patient subpopulation. Once an optimal heart rate is achieved, the decision has to be made for
long-term management.3 Management of persistent/chronic AF may involve conversion to
sinus rhythm (with drugs or electricity or both), or controlling the rate as in permanent AF. The
decision to choose either management pathway depends on many factors, but general
guidelines exist that help decide what treatment modality would produce optimal results for
the patient. This research project is a comparative analysis of rate and rhythm control, and the
health related quality of life implications to the patient, using three different studies that look
at various aspects of AF and common comorbidities. Among the three studies analyzed, the
specific endpoints measured and compared were all-cause mortality, cardiovascular mortality,
arrhythmic/sudden death, ischemic stroke, systemic embolism, major bleeding, health-related
quality of life (HRQoL), symptoms, left ventricular systolic function, exercise tolerance, and
basic hematology and biochemistry lab work.
Scenario: A 70 year old male presents to the clinic with shortness of breath, chest pain, and an
episode of syncope. The patient was found to now have comorbid heart failure. He was
previously diagnosed with atrial fibrillation in 2014 and is currently on a regimen of warfarin
and atenolol. After management of the patient’s current symptoms, the patient would like to
know how the treatment of his atrial fibrillation will change.
P

Patient/ population

Patients with persistent atrial fibrillation

I

Intervention

Rhythm control

C

Comparison

Rate control

O

Outcome

Quality of Life

Clinical Question: Among patients with persistent atrial fibrillation, does rhythm control result
in a better quality of life than rate control?
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Methods
An initial literature search was performed using PubMed and Google Scholar and the
terms “atrial fibrillation rate versus rhythm” and “rate rhythm atrial fibrillation” respectively.
Inclusion criteria was limited to randomized control trials involving patients with atrial
fibrillation, and including the comparison of rate control and rhythm control. Studies were
excluded if they were not in English, were performed before 2005, involved animals, or if they
involved comorbid diseases. Studies were further excluded based on the outcome assessment
used. See flow chart (see Appendix A). Ten articles were assessed for application. Seven were
excluded, because they were meta-analysis and not original studies. Three studies were
included in this literature review:
A. Health-related quality of life in patients with atrial fibrillation treated with rhythm
control versus rate control. Andrew et al5.
B. Rate versus rhythm control in atrial fibrillation and clinical outcomes: Updated
systematic review and meta-analysis of randomized controlled trials. Caldeira et al6.
C. A randomized controlled study of rate versus rhythm control in patients with chronic
atrial fibrillation and heart failure (CAFÉ-II Study). Shelton et al7.

Results
Study A
Health-Related Quality of Life in Patients with Atrial Fibrillation Treated with Rhythm Control
versus Rate Control. Andrew et al5.
Objective
The objective of this study was to assess patients’ perception of their quality of life after
being treated with medical rate or rhythm control for 1 year.
Study Design
Researchers conducted an international, prospective cohort study of patients newly
diagnosed with atrial fibrillation (< 1 year onset), found through the Registry on Cardiac Rhythm
Disorders Assessing the Control of Atrial Fibrillation or RECORD-AF database. Patient
recruitment was conducted from May 2007 until April 2008 and included 5,604 patients from
21 countries in Europe, North and South Americas, and Asia.
Patients were assigned to a treatment group as determined by a treating cardiologist at
a baseline visit. Rhythm control was described as antiarrhythmic drugs including class I, sotalol,
or other class III. Rate control was defined as the use of an AV nodal blocker to include a nonsotalol beta-blocker, calcium channel blocker, or digoxin. The baseline characteristics (See
Appendix B) of the cohorts were assessed with a propensity score model. The model was used
4
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to determine the likelihood that a patient would fall into a particular treatment cohort prior to
assignment; this was done to decrease confounding due to covariates.
The researchers hypothesized that improvements in quality of life would be seen in both
cohorts, but thought that the magnitude of improvement in the rhythm cohort would be
greater than that of the rate cohort. To assess quality of life (QoL), the University of Toronto
Atrial Fibrillation Severity Scale (see Appendix C) was given at baseline, 3 months, and 1 year.
The questionnaire included patient-reported information about seven atrial fibrillation-related
symptoms assigned a severity score from zero to five, five being the most severe. Scores total
from 0-35 with higher values indicating a worse patient perception of quality of life secondary
to atrial fibrillation.
The primary outcome measured was the difference in the QoL reported from baseline to
1 year. Results were analyzed per protocol with patients who died during the study, those with
incomplete questionnaires at baseline or 12 months, and those needing to change treatment
prior to the study conclusion, excluded from the study results. The results were analyzed using
Student t tests – a method that compares the averages of study groups to find any statistically
significant differences 8.
Results
After exclusions, 2,439 patients were sorted into rate and rhythm control cohorts
(containing 1,267 and 1,172 patients respectively). At baseline, the mean Atrial Fibrillation
Severity Scale (AFSS) score was the same in both cohorts (See Table 1). At 12-months, AFSS
decreased, or improved, by 2.82 points in the rhythm cohort, while the rate cohort saw an
improvement, or decrease, in AFSS score by 2.11 points. The improvements showed statistical
significance with a p-value <0.01.
Cohort

Mean AFSS Score at Baseline

Mean AFSS Score at 12-months

Rate

8.7 ± 7.0

6.5

Rhythm

8.7 ± 7.0

5.8

Table 1: Table shows average Atrial Fibrillation Severity Scale (AFSS) scores of the cohorts at
baseline and at the final 12-month follow up.

While the results statistically favor rhythm control, the researchers proposed that
there was also clinical significance in the findings. The researchers correlated an
improvement in QoL by ~3 points, as demonstrated by the rhythm cohort, to an
improvement by one class in the Canadian Cardiovascular Society Severity of Atrial
5
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CSS-SAF9.

Fibrillation or
The CCS-SAF is a clinical tool used to assess atrial fibrillation
severity based on patient symptoms and impact on QoL (see Appendix D). The impact of
symptoms on patient functionality dictates which class of atrial fibrillation severity they
fall into; class 0 being the least severe, class 4 being the most severe9. The researchers
suggested that the improvements in QoL of the rhythm control group after 12 months
were associated with decreased atrial fibrillation related emergency room visits and
hospitalizations. Thus suggesting that treating atrial fibrillation with rhythm control drugs
would decrease healthcare related costs associated with emergency room visits and
hospitalizations5.
In addition to the results of the study objective, the researchers also assessed the
improvement of quality of life in the subgroups of those with paroxysmal AF and those
with comorbid heart failure and AF. In the 1,255 patients with paroxysmal AF at baseline,
780 and 475 were assigned to the rhythm and rate cohorts respectively. A trend toward
rhythm control was demonstrated by the greater improvement (0.94 point) of AFSS scores
between rhythm and rate cohorts at 12-month follow up (See Table 2). Among the 400
patients diagnosed with AF and heart failure at baseline (170 rhythm cohort, 230 rate
cohort), the researchers observed no statistically significant difference between AFSS
scores at 12-months - as indicated by the p-value (0.40); there were however, general
improvements of AFSS scores in this comorbid subgroup.
Subgroup

Cohort

AFSS Improvement seen at 12-months (points) p-value

Rate

1.57

Paroxysmal AF

0.03
Rhythm

2.51

Rate

2.68

AF and Heart Failure

0.40
Rhythm

2.02

Table 2: Table shows the amount of improvement (or decrease) in Atrial Fibrillation Severity Scale scores at 12month from baseline averages and p-values analyzing the statistical significance of the differences between the
two cohorts.

Study B
Rate versus rhythm control in atrial fibrillation and clinical outcomes: Updated systematic
review and meta-analysis of randomized controlled trials. Caldeira et al6.
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Objective
The study objective was to compare the clinical efficacy of rate and rhythm strategies in
patients with AF not due to cardiac surgery.
Study Design
This study, involving a total of 7,499 participants with AF, is a systematic review and
meta-analysis of 8 randomized controlled trials (comparing rate and rhythm control strategies),
retrieved by systematic search of PubMed and the Cochrane Central Register of Controlled
Trials (CENTRAL) databases. Keywords used in the search were: rate, beta- blocker, acebutolol,
atenolol, bisoprolol, carvedilol, esmolol, metoprolol, nadolol, pindolol, propranolol, timolol,
calcium-channel blocker, verapamil, diltiazem, digitalis, digoxin, rhythm, amiodarone, sotalol,
propafenone, disopyramide, dofetilide, flecainide, ibutilide, dronedarone and azimilide,
mortality, death, stroke, embolism, thromboembolic, thromboembolism, bleeding and atrial
fibrillation. Boolean operators “AND” and “OR” were used to combined search terms.
Postoperative and post-percutaneous intervention studies were excluded using the Boolean
operator “NOT”. Other inclusion criteria were randomized control trials (RCTs) comparing
pharmacological approaches to maintaining rate or rhythm control in patients with AF, studies
with mean participant age greater than 55 years and studies that had intention to treat (ITT)
analysis (or provided data for its calculation). Quasi-randomized studies and prospective cohort
studies were excluded. Selected studies were assessed by one review author and then
reassessed by another. Data was retrieved and analyzed using the RevMan software version
5.1.4 (for pooled data) and the Mantel-Haenszel method (for dichotomous outcomes). Then
relative risk and 95% CI calculated. The specific end-points measured and compared were: allcause mortality, cardiovascular mortality, arrhythmic/sudden death, ischemic stroke, systemic
embolism and major bleeding. In all the selected trials, interventions were unblinded to
physicians and patients.
Results
With these selection criteria, 8 studies were selected for analysis (PIAF, RACE, AFFIRM,
STAF, HOT CAFÉ, AF-CHF, J-RHYTHM and CAFÉ-II studies). The mean age of the patients in the
selected studies was 68 years and majority were men in all the trials included (63.4-82.0%). The
length of follow-up ranged from 1- 3.5 years with a weighted mean follow up duration of 2.9
years. Prevalence of hypertension ranged from 42.8% to 64.3%, coronary artery disease 7.4% to
43.5% and valvular disease from 4.9% to 17%. Two of the studies (AF-CHF and CAFÉ-II) included
only patients with heart failure (100% heart failure prevalence) whereas 1 study (PIAF) provided
no heart failure data. In-between, heart failure prevalence ranged from 3.6% to 70%. Three of
the studies (AFFIRM, AF-CHF and J-RHYTHM) had cross over rates greater than 15%.
7
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All-cause mortality, cardiovascular mortality, arrhythmic/sudden death, ischemic
stroke, systemic embolism and major bleeding were all found to be similar for both rate and
rhythm control groups in all the selected studies, and also when all data are pooled in the metaanalysis. There were observed differences between the two treatment groups in some of the
trials, howbeit, not statistically significant. These “statistically insignificant” differences may
however, have clinical significance for specific sub-populations. For instance, in the AFFIRM trial
(which together with the AF-CHF trial contributed most of the data), arrhythmia/sudden death
incidence was lower in the rhythm control group, making rhythm control possibly a better
strategy than rate control when considering risk of death from fatal arrhythmias. Also, in most
of the studies the rate control group showed less ischemic stroke and systemic embolism,
though not statistically significant. Another observation is that analysis of trials with mean age
less than 65 years revealed better outcomes for the rate control group.
It is noteworthy that all-cause mortality included both cardiovascular and
noncardiovascular mortality. In the AFFIRM study pulmonary diseases (especially pneumonia)
and lung cancer constituted the majority of non-cardiovascular deaths. Death rate due to
amiodarone toxicity was calculated, because amiodarone was prescribed to most patients in 4
of the 6 trials (see table 2) reporting data on antiarrhythmic drug use. Though death due to
amiodarone toxicity was relatively low (3 out of 39 pulmonary deaths in the rhythm control
group), its calculation was deemed important since amiodarone is prescribed much longer than
the average duration of the studies, and therefore likely to result in a higher mortality rate than
the meta-analysis revealed. The results from individual studies are summarized in Tables 3 and
4. Figures 1 and 2 represent the forest plots for all-cause and cardiovascular mortality
respectively.
From Table 3, it can be inferred that all outcomes showed no statistical heterogeneity
(except Ischemic stroke which showed I2 of 26%). Since statistical heterogeneity was initially
defined as I2 of greater than 50%, outcomes were assumed to show no statistical
heterogeneity. However, relative risk computations were based on random effects model since
there was significant clinical heterogeneity among study participants (generally, relative risks
are computed using the fixed effects model if study groups show no significant heterogeneity,
and random effects model is used if significant heterogeneity exists). To demonstrate that the
selection of either random or fixed effects model to compute relative risks made no statistical
difference in the interpretation of the outcomes (since all confidence intervals included 1),
relative risk computations using the fixed effects model are presented side-by-side with those
of the random effects model for easy comparison. Another observation from Table 3 is that the
confidence intervals that were used were different for each of the outcomes, and exactly what
informed the choice of these specific confidence intervals is unclear. Since confidence intervals
8
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determine whether or not the calculated relative risk is statistically significant, an explanation
of how the various confidence intervals were arrived at would have added more clarity to the
interpretation of the results.

Outcome

Studies

Patients

Rate

Rhythm

Random Effects
(RR [95% CI])

Fixed Effects
(RR [95% CI])

Heterogeneity
I2 (%)

All-cause
mortality

8

7499

3738

3761

0.95
[0.85-1.05]

0.94
[0.84-1.04]

0

Cardiovascular
mortality

7

6676

3334

3342

0.99
[0.87-1.13]

0.99
[0.87-1.13]

0

Arrhythmic/
sudden death

5

6410

3202

3208

1.12
[0.91-1.38]

1.12
[0.91-1.38]

0

Ischemic
stroke

4

5288

2632

2656

0.89
[0.52-1.53]

0.92
[0.70-1.23]

26

Systemic
embolism

6

6062

3013

3049

0.89
[0.69-1.14]

0.88
[0.68-1.12]

0

Major
bleeding

5

5810

2888

2922

1.10
[0.89-1.36]

1.10
[0.89-1.36]

0

Table 3: Depicts no statistical difference between the two groups (rate versus rhythm) with regards to all-cause
mortality, cardiovascular mortality and mortality due to fatal arrhythmias. The same holds true for all other events
measured. CI: confidence interval; RR: risk ratio

PIAF
% Amiodarone
in rhythm
100
control group

RACE

AFFIRM

STAF HOT CAFÉ

AF-CHF

J-RHYTHM

CAFÉ II

N/A

62.8

42

82

0.5

80

56.7

Table 4: Shows the percentage of patients in the various RCTs who received Amiodarone as the antiarrhythmic.
With the exception of the RCTs J-Rhythm and STAF in which less than half of the patients received amiodarone, all
in all other trials (except RACE) majority of patients received amiodarone. No amiodarone data was available for the
RACE trial.
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Figure 1: Forest plot of all-cause mortality. The risk ratios (in the given confidence intervals) for individual studies,
and the composite data all show no statistically significant difference between the two groups (rate and rhythm
control groups)6.

Figure 2: Forest plot of cardiovascular mortality. The relative risks (in the given confidence intervals) for individual
studies, and the composite data all show no statistically significant difference between the two groups (rate and
rhythm control groups)6.

Study C
Randomized, controlled study of rate versus rhythm control in patients with chronic atrial
fibrillation and heart failure (CAFÉ-II Study). Shelton et al8.
10
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Objective
The objective of the study was to investigate whether restoring sinus rhythm could
improve cardiac function, symptoms, exercise capacity, and quality of life (QoL) in patients with
chronic heart failure.
Study Design
The study was a RCT involving 61 patients with chronic AF and heart failure. Other
inclusion criteria were age 18 years and older and symptomatic heart failure of NYHA Class II or
worse with evidence of systolic dysfunction on echocardiography. Patients with
contraindication to oral anticoagulants were excluded. The patients were randomly assigned to
one of two groups-rate control group and rhythm control group. The rhythm control group was
given at least 3 months of amiodarone prior to biphasic electrical cardioversion. Once sinus
rhythm was successfully achieved, they were then continued on long-term amiodarone, in
addition to beta-blocker and/or digoxin to keep heart rate <80 bpm at rest and <110 bpm after
walking. The rate control group was treated with only beta-blocker and/or digoxin to achieve
the above heart rates. Both groups received chronic anticoagulation throughout the study
unless contraindications developed. All patients had their heart failure treatment optimized.
Symptoms, walk distance (6-minute corridor walk test, or 6MWT), QoL and cardiac
function were assessed at baseline and 1 year. To assess these parameters, patients were
examined, had 12-lead EKG, 2-dimensional echocardiography, had blood drawn for standard
hematology and biochemistry profiles, and NT-proBNP determination. NT-proBNP is the Nterminal amino acid sequence cleaved in vivo from the prohormone (proBNP), and is used to
quantify/compare left ventricular dysfunctions (the higher the blood level of NT-proBNP, the
worse the left ventricular function). Though the authors did not clearly state the purpose of NTproBNP measurements, they may have been used to supplement the comparison of left
ventricular dysfunction which was mainly qualitative (i.e. NT-proBNP can serve as a semiquantitative measure in the comparison of the two groups).
Patients were reviewed at four monthly intervals. During each review cardiovascular
events were recorded and a 12-lead EKG obtained. Rate control at rest and during a 6-minute
corridor was performed. At 1 year the above routines were done in addition to a 2-D
echocardiography and blood drawn. QoL was assessed by having patients fill out a generic
questionnaire (the Medical Outcomes Study Short Form-36, SF-36) and a disease specific
questionnaire (the Minnesota Living With Heart Failure questionnaire, MLWHF). Left ventricular
(LV) function was assessed qualitatively on a 6-point scale as normal, mild, mild-to-moderate,
moderate, moderate-to-severe and severe; this was done because of the difficulty associated
with measuring ejection fraction in AF. The primary outcome measured was QoL at 1 year.
11
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Secondary outcomes were proportion in sinus rhythm (SR), MLWHF, NT-proBNP, 6MWT and
severity of LV systolic dysfunction. All analyses were based on intention-to-treat.
Results
Of the 61 patients, 31 were randomly assigned to the rate control group and 30 to the
rhythm control group. The median duration of AF was 14 months. Before randomization most
patients were already receiving beta-blockers (80%), ACE inhibitors (89%) and loop diuretics
(90%). Two patients died (one from each group) during follow-up. Warfarin was discontinued in
1 person (from the rate control group) due to recurrent epistaxis, and 1 person (also from the
rate control group) underwent elective pacemaker insertion due to bradycardia.
At baseline 61% of the rate control group was already at the target resting heart of <80
bpm and post-exercise target heart rate of <110 bpm. The mean ventricular rate at rest was 73
bpm, post-exercise was 100 bpm at baseline. By 1 year the mean resting heart rate had
dropped to 70 bpm and post-exercise heart rate also had dropped to 87 bpm. Also 65% and
84% of the rate control group were already on digoxin and beta-blocker respectively at
baseline. At 1 year 84% and 90% were on digoxin and beta-blocker respectively.
For the rhythm control group beta-blocker use at baseline and at 1 year were 83% and
93% respectively. Amiodarone was started in all patients in the rhythm control group and at 1
year 24 (80%) patients were still on amiodarone. Cardioversion restored sinus rhythm in 18 of
23 (78%) patients in whom it was attempted. One person declined electrical cardioversion and
remained in AF throughout the study. Four patients required a second electrical cardioversion
due to AF recurrence. Overall, 26 (87%) patients were converted from AF to SR at some point
during the study. The prevalence of AF in the rhythm control group was 53% at 4 months, 30%
at 8 months and 34% at 1 year. At 1 year 6 (20%) patients had crossed over to the rate control
group.
Regarding QoL, patients in the rhythm control group showed a greater improvement
when SF36vII was used (See Figures 3 and 4). When MLWHF was used, the difference in QoL
was not statistically significant. However, a post-hoc analysis which compared only the rhythm
control patients able to achieve sinus rhythm to the rate control group showed superior results
in favor of the rhythm control with both SF36vII and MLWHF questionnaires. A post-hoc
analysis is a statistical analysis performed after the the study is concluded. It is termed post-hoc
because it was not included in the initial planning of the study; simply put, it is taking a second
look at the data to see what else might be found. The NYHA class remained the same between
baseline and 1 year, and there was no difference between the two treatment strategies (rate
versus rhythm control).
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Figure 3. Comparison of change in QoL scores over 1 year between rate and rhythm control groups.
The p values denotes the comparison between groups. Bars represent mean QoL score and whiskers
represent the standard error of the mean. *Inverse Minnesota Living with Heart Failure (MWLHF)
score; unlike SF-36 vII, a lower score indicates a better QoL.

Figure 4. Comparison of change in QoL scores over 1 year between rate and rhythm control groups
(comparing only those who maintained SR in the rhythm control groups with those achieving
adequate rate control in rate control group). Bars represent mean QoL score, and whiskers
represent the standard error of the mean. *Inverse Minnesota Living with Heart Failure (MWLHF)
score; unlike SF-36 vII, a lower score indicates a better QoL.

6MWT distances at baseline for rate and rhythm control groups were respectively 307
meters and 352 meters. At 1 year the respective 6MWT distances were 311 meters and 368
meters (See Figure 5). Comparing the patients in rate control group who achieved adequate
13
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rate control with the patients in the rhythm control group who achieved sinus rhythm, the
mean changes in 6MWT distance were -10 meters and +21 meters respectively.

Figure 5. Six minute walk test distance at baseline and 1 year.

At baseline, LV function was designated as “moderately” impaired for both groups. The
rhythm control group achieved a greater improvement in LV function at 1 year compared to the
rate control group- the median severity of LV systolic dysfunction at 1 year in the rhythm
control group improved from “moderate” to “mild” while the parameter remained “moderate”
in the rate control group.
NT-proBNP was similar (not statistically significant) for both groups at baseline. For rate
control group median was 1835 pg/ml (ranged from 947 to 2546). For the rhythm control group
the median was 1285 pg/ml (ranged from 913 to 1624). At 1 year the median NT-proBNP for
rate control group was 1480 pg/ml (1074 to 2681) and for rhythm control group was 685 pg/ml
(347 to 1176). Over the 1 year period a comparatively greater reduction in NT-proBNP was seen
in the rhythm control group than the rate control group (-0.03 vs -0.23log [NT-proBNP] for rate
and rhythm control respectively). The greatest reduction in (median) NT-proBNP over the 1year
period was seen in those patients maintaining SR (1472 to 458 pg/ml).
For the hematology and biochemistry data, there was about 1.0 g/dl reduction in
hemoglobin (Hgb) over 1 year in the rhythm group (14.2 at baseline to 13.4 at 1 year).
Creatinine (Cr) increased by 18.5 micromol/L (from baseline of 105 to 121 at 1 year). On the
other hand there was no significant change in the corresponding data for the rate control group
(baseline Hgb 13.5 vs Hgb at 1 year 13.2; baseline Cr of 118.8 vs Cr at 1 year 18.8). Although the
14
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fall in the hemoglobin and the rise in creatinine respectively, in the rhythm control group at 1
year were statistically significant, their clinical significance was not clearly discussed in the
article. However, a possible significance would be that they may have resulted from side effects
of the antiarrhythmics used. If this is so, then the changes represent a disadvantage of rhythm
control (since medication side effects are an important factor in management decisions).
Thyroid Stimulating Hormone (TSH) remained fairly unchanged at baseline and at 1 year for
both groups.

Discussion
Overall, there was no clear benefit from the choice of treatment strategy in atrial
fibrillation between rhythm and rate control. There were however, trends toward rhythm
control in subpopulations of patients with AF6,7 (specifically those with comorbid heart failure)
and when assessing quality of life based on symptom severity5.
There were notable differences between the cohorts at baseline in Study A 5. The rate
control cohort was older, a greater percentage had persistent AF, and had high incidence of
comorbidities: heart failure, hypertension, diabetes mellitus, and prior stroke (CHADS 2).
Although these were mentioned by the researchers, it was never discussed that the differences
could have negatively impacted the success of the rate cohort. It is also worth mentioning that
while this study focuses on patient perception of quality of life through decreased severity and
frequency of symptoms, it fails to address the major sequelae often associated with atrial
fibrillation. While symptomatic control of AF is important, it must be understood that lack of, or
improvement in symptoms does not necessarily equate to decreased risk of adverse events or
mortality associated with AF - as it can often be asymptomatic and still associated with high
morbidity and mortality2.
Strengths of this study include the addressing of the study’s limitations and assessment
methods. Patients included in the study had been diagnosed up to 1 year prior, giving them
time to have previously been treated before the study. The researchers propose that the
success of the rhythm cohort could have been confounded by prior treatment with
antiarrhythmic drugs. In addition, crossover was proposed to have had diluted patient
perception of quality of life improvements upon primary analysis. It was also discussed that
patients yielding the greatest improvements in quality of life were those that were more likely
to have had more severe symptoms at baseline. Thus, it was concluded that severity of
symptoms largely impacts perceived improvement with treatment.
Further, this study adds a different perspective to previous evaluations of rate and
rhythm control of atrial fibrillation. Whereas previous studies largely assess the success of
treatment based on the objective occurrence of adverse events, this study assessed treatment
15
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success from the subjective point of view of the patient. Though it can be argued that the use
of a questionnaire is too subjective, this is one of few studies that found statistically significant
trends toward rhythm control; perhaps this was due to the method of analysis. When
considering patient involved care, subjective studies like this are beneficial in that they take
into account clinical presentation and patient point of view.
Statistically, the results of Study A were found to be significant with a p-value <0.01.
However, this significance may not have clinical application in that there was only a 0.75 point
difference between the final AFSS scores of the two cohorts. While the rhythm cohort did
experience a greater improvement in quality of life from baseline, the minimal difference
between the cohorts is borderline unremarkable. Further, the researchers originally defined
clinically significant improvement as an AFSS score that decreased, or improved, by ≥3 points.
Neither cohort had an overall clinically significant improvement as defined by the study itself
(final rate improvement, 2.11 points; final rhythm improvement, 2.82 points). Given this
interpretation of the results, it is questionable as to whether in general, rhythm control is
actually better than rate control in the reduction of symptom severity and perceived
improvement of quality of life in AF.
Strengths of Study B6 include the inclusion of randomized control trials (RCTs) only. Also
the number of participants in each individual study and in the overall meta-analysis were
relatively large. Another strength is that, besides the PIAF and RACE trials (that showed some
differences in baseline characteristics), all the other selected studies had participants with
similar baseline characteristics. This ensures homogeneity and a fair comparison of results.
However, there are potential sources of error; though the studies were all RCTs, all of them
were unblinded to both physicians and patients, which is a potential source of bias. One source
of unblinding is the physical nature of electrical cardioversion. This could not be remedied
because the use of fake electrical cardioversion to ensure blinding raised an ethical dilemma
and therefore was not used. In addition, though the selected studies were considered
homogenous by calculation, the statistically “insignificant” heterogeneity may, in fact, be
significant in reality. Lastly, for studies that did not supply data for systemic embolism, this was
calculated by adding ischemic stroke and systemic embolism, with the assumption that in AF
most ischemic strokes originate from cardiac emboli. However, some ischemic strokes in AF
may result from thrombosis of cerebral vessels, making this calculation likely inaccurate.
Overall, Study B results showed no statistical difference between the two treatment
groups with regards to mortality (both all-cause and cardiovascular mortality). For all-cause
mortality, for instance, the calculated death risk ratio was 0.95 with a 95% confidence interval
of 0.86-1.05 (for random effect calculation) and relative risk of 0.94 with a 95% CI of 0.84-1.04
(using fixed effects calculation). Similarly, there was no statistical difference between the two
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regarding all other outcomes measured. Besides the pooled data in the meta-analysis, each of
the studies individually showed no statistical difference in mortality (both all-cause and
cardiovascular mortality) and in all the other outcomes. However, when certain categories of
studies were pooled together, there seems to be an urge of one strategy over the other when
specific end-points were considered. For instance, when trials with at least 50% of participants
with comorbid heart failure were pulled together, there was significantly lower occurrence of
systemic embolic events in the rate control group. The calculated relative risk was 0.43 (95% CI:
0.21-0.89). This could be explained by the fact that heart failure is a component of the CHADS2
score, so such patients would have been on chronic anticoagulation, thereby reducing their risk
of systemic embolic events. In light of the fact that the literature tends to favor rhythm control
in young/middle-aged patients10, the observation that analysis of trials with mean age less than
65 years revealed better outcomes for the rate control group, is unusual. This may have
occurred purely by chance as the sample size involved is not representative of the general
young/middle-age population.
Strengths of Study C7 include randomization and the fact that both groups had similar
baseline characteristics. However, treatment was unblinded to both physicians and patients,
and this could have affected all measured parameters (except the lab tests). Another limitation
is the relatively small sample size (a total of 61 participants). Also, because only symptomatic
paroxysmal AF in the rhythm control group would have been reported, asymptomatic
paroxysmal AF (in the rhythm control group) in between patient visits could have been missed.
This, if significantly prevalent, could have affected the parameters for the rhythm control
group, and this effect was not accounted for.
Intention to treat (rather than per-protocol) analysis was used in the study, thus
reducing bias. However, the downside to using intention to treat analysis is that the effect of
restoring sinus rhythm in the rhythm control group could have been diluted by the inclusion of
patients in whom cardioversion to sinus rhythm was unsuccessful.
The results in Study C seemed to indicate an urge of rhythm control over rate control in
most of the measured outcomes. QoL, exercise performance and LV function all showed
significantly larger improvements in the rhythm control group. Theoretically, improvement in
left ventricular function would be expected to decrease strain in the ventricles thereby reducing
NT-proBNP, and this is what was observed in the trial. However, creatinine reduced significantly
more in the rate control group than the rhythm control group. This could have occurred as a
result of possible nephrotoxicity of some antiarrhythmic medications; amiodarone, for
example, is nephrotoxic when combined with statins, and some of these patients may have
been on statins concurrently (though no data was reported on statin use).
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Application to the Patient
Scenario: A 70 year old male presents to the clinic with shortness of breath, chest pain, and an
episode of syncope. The patient was found to now have comorbid heart failure. He was
previously diagnosed with atrial fibrillation in 2014 and is currently on a regimen of warfarin
and atenolol. After management of the patient’s current symptoms, the patient would like to
know how the treatment of his atrial fibrillation will change.
With the development of comorbid heart failure, the best option for treatment of this
patient’s atrial fibrillation is now is rhythm control. Due to the development of comorbid heart
failure despite rate control, the conclusions from the research recommend a trial of rhythm
control6,7 in addition to his current regimen of warfarin and atenolol. It is important to maintain
rate control in patients with atrial fibrillation, and anti-coagulation with warfarin to prevent
thrombosis.

Conclusion
The decision to choose rate control or rhythm control for treatment of atrial fibrillation
depends on several factors. The presence and type of comorbidities, the duration of AF, age of
the patient, medication side effects, symptoms, and patient preferences must all be considered
in tandem. The majority of available studies do not demonstrate a clear advantage of rhythm
control over rate control or vice versa. Even so, in the ones that trend towards rhythm control,
the differences in improvement seem to be small and make it difficult to confidently say that
rhythm control is the best option for treatment. In addition, given the heterogeneity of the AF
patient population, a “one-size-fits –all” management protocol is impractical. While these
findings make it difficult to determine a general protocol for the treatment of AF, they do
provide a framework that may be able to help clinicians, along with patient input, decide on
which treatment method is “best”.
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Appendix
Appendix A: PRISMA Flow Diagram
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Appendix B: Baseline patient demographics of Study A - Health-Related Quality of Life in
Patients with Atrial Fibrillation Treated with Rhythm Control versus Rate Control. Andrew et al 5.
Characteristic
Rhythm Cohort (n=1,267) Rate Cohort (n=1,172)
Male sex
740
686
Age (mean ± SD)
66.4 ± 11.8
68.8 ± 11.5
Systolic BP, mm Hg (mean ± SD)
133.2 ± 19.1
132.5 ± 19.7
Resting heart rate, bpm (mean ± SD) 75.8 ± 21.3
77.8 ± 18.3
Paroxysmal AF
780
475
Persistent AF
403
640
CHADS2 score ≥2
461
540
Antithrombotic at baseline
1067
1035
Vitamin K antagonist use
721
773
History of Heart Failure
170
230
History of AF symptoms
1027
839
Smokers (current or former)
546
520
Class I drug within the last month
224
23
β-blocker within the last month
661
846
Class III drug within the last month
550
86
CCB use within the last month
121
223
Digoxin use in the past month
169
329
AFSS score (mean ± SD)
8.7 ± 7.0
8.7 ± 7.0
SD indicates standard deviation; BP, blood pressure; AF, atrial fibrillation; CHADS 2 score, prior
stroke; CCB, calcium channel blocker
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Appendix C: University of Toronto Atrial Fibrillation Severity Scale (questionnaire) used in Study
A - Health-Related Quality of Life in Patients with Atrial Fibrillation Treated with Rhythm Control
versus Rate Control. Andrew et al5.
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Appendix D: Canadian Cardiovascular Society Severity of Atrial Fibrillation used in Study A Health-Related Quality of Life in Patients with Atrial Fibrillation Treated with Rhythm Control
versus Rate Control. Andrew et al5.
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